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1. INTRODUCTION 
 
Worldwide, high blood pressure (HBP) is estimated to cause 7.1 million deaths, about 
13 percent of the global fatality total. Across world health organization (WHO) regions, 
research indicates that about 62 percent of strokes and 49 percent of heart attacks are caused 
by HBP.
1
 Increasing awareness and diagnosis of hypertension and improving control of BP 
with appropriate treatment are considered critical Public health initiatives to reduce 
cardiovascular morbidity and mortality. The Seventh Report of the Joint National Committee 
(JNC7) on the Detection, Evaluation, and Treatment of HBP was developed to aid clinicians 
in the management of hypertension.
2 
 
The ―Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure‖ provides a new guideline for 
hypertension prevention and management. According to JNC – 7 guidelines in persons older 
than 50 years, systolic blood pressure greater than 140 mmHg is a much more important 
cardiovascular disease (CVD) risk factor than diastolic blood pressure.
2
 
 
The WHO estimates that 600 million people with HBP are at risk of heart attack, 
stroke and cardiac failure. A study of hypertension in six European countries, Canada and the 
United States showed the average blood pressure (BP) was 136/83 mm Hg in the European 
countries and 127/77 mm Hg in Canada and the United States, among men and women ages 
35–74 years. For all age groups, BP measurements were lowest in the United States and 
highest in Germany.
1 
Worldwide, Indo-Asian people are among the populations at highest 
risk for cardiovascular disease.
3
 Evidence also suggests that associations between body mass 
index (BMI), percentage of body fat and chronic disease may differ between Indo-Asian and 
European populations.
4,5
 Because of the observed differences between populations, the 
International Association for the Study of Obesity and the International Obesity Task Force 
have suggested lower BMI cutoff values for the definitions of overweight (23.0–24.9 kg/m2) 
and obesity (25.0 kg/m
2
 or greater) in Asian populations.
6
 
Dubey VD
7
 
carried out one of the earliest study in India (1954), documented 4% 
prevalence of hypertension (criteria:>160/95) amongst industrial workers of Kanpur. During 
1984-87 Gopinath and Chadha
8,9
 
et al., reported the prevalence of hypertension in Delhi 
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(criteria: >160/90) to be 11% among males and 12% among females in the urban areas and 
4% and 3% respectively in rural areas. Another two studies carried out in rural areas of 
Haryana
10
 
(1994-95) demonstrated 4.5% prevalence of hypertension (JNC V criteria) while 
urban areas of Delhi had a higher prevalence of 45% during 1996-97.
11
 
Few studies were 
carried out comparing different socio economic groups. The initial study from urban Chennai, 
Mohan
12
 et al.,
 
reported 8.4% prevalence of hypertension among men and women aged 20 
years and above and belonging to the low socio economic group (based on household 
income, occupation and dietary pattern). Similarly, in the middle socio economic group had a 
higher prevalence (15%) during 1996-97. A study conducted in the urban areas of Chennai 
during 2000
13
 
(age group < 40) reported a higher prevalence of hypertension (54%) among 
low income group (monthly income < Rs 30000/annum and 40% prevalence among high-
income group (monthly income < Rs 60000/annum). Misra
14
 et al.,
 
reported 12% prevalence 
of hypertension in the slums of Delhi. From south India, Kutty VR
15
 
carried out hypertension 
prevalence study (criteria: < 160/95 mm of Hg) in rural Kerala during 1991 in the 20 plus age 
group and the prevalence was found to be 18%. Later studies in Kerala (Criteria: JNC VI) 
reported 37% prevalence of hypertension among 30-64 age group
16 
in 1998 and 55% among 
40-60 age group
17
 
during 2000. A higher prevalence of 69% and 55% was recorded among 
elderly populations aged sixty and above in the urban and rural areas respectively during 
2000.
18
 
 
Interactions between genetic and hemodynamic factors cause hypertensive heart 
disease in patients with arterial hypertension. The resulting structural and functional 
adaptations lead to increased left ventricular (LV) mass, diastolic dysfunction, congestive 
heart failure (CHF), arrhythmias and abnormalities of myocardial perfusion due to 
microvascular endothelial dysfunction. Consequently, hypertensive individuals with 
hypertensive heart disease are more prone to myocardial infarction, congestive heart failure, 
stroke, and sudden death then persons with hypertension alone. 
19
 
 
1.1 HYPERTENSION 
 
Hypertension is a common disease that is defined simply as persistently elevated 
arterial blood pressure (BP). Increasing awareness and diagnosis of hypertension and 
improving control of BP with appropriate treatment are considered critical Public health 
Dept.of Pharmacy Practice, JKKN, Komarapalayam Page 6 
 
 
initiatives to reduce cardiovascular morbidity and mortality. It is a heterogeneous medical 
condition. In most patients it results from unknown pathophysiologic etiology (essential or 
primary hypertension). While this form of hypertension cannot be cured, it can be controlled. 
A small percentage of patients have a specific cause of their hypertension (secondary 
hypertension). It is defined simply as persistently elevated arterial BP. The JNC7 
classification of BP in adults (age > 18 years) is based on the average of two or more 
properly measured BP readings from two or more clinical encounters
2
. It includes four 
categories, with normal values considered to be a systolic blood pressure (SBP) of less than 
120 mm Hg and a diastolic blood pressure (DBP) of less than 80mmHg. Prehypertension is 
not considered a disease category but identifies patients whose BP is likely to increase into 
the classification of hypertension in the future. There are two stages of hypertension, and all 
patients in these categories need drug therapy. 
 
Table. 1 Classification of Blood Pressure in Adults (Age ≥ 18 Years) a 
 
Classification Systolic BP(mmHg) Diastolic BP(mmHg) 
Normal Less than 120 Less than 80 
Prehypertension
b
 120-139 80-89 
Stage 1hypertension 140-159 90-99 
Stage 2hypertension Greater than or equal to 160 Greater than or equal to 100 
 
a Classification determined based on the average of two or more properly measured seated 
BP measurements from two or more clinical encounters. If systolic and diastolic blood 
pressure values yield different classifications, the highest category is used for the purpose of 
determining a classification. 
b For patients with diabetes mellitus or chronic kidney disease, values <130/80 mm Hg are 
considered above goal. 
 
1.2. ETIOLOGICAL CLASSIFICATION 
 
In most patients it results from unknown pathophysiologic etiology (essential or 
primary hypertension). While this form of hypertension cannot be cured, it can be controlled. 
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A small percentage of patients have a specific cause of their hypertension (secondary 
hypertension). There are many potential secondary causes that are either concurrent medical 
conditions or are endogenously induced. If the cause of secondary hypertension can be 
identified, hypertension in these patients potentially can be cured. 
 
1.2.1 Primary hypertension 
 
Over 90% of individuals with hypertension have essential hypertension (primary 
hypertension).
2
 Numerous mechanisms have been identified that may contribute to the 
pathogenesis of this form of hypertension, so identifying the exact underlying abnormality is 
not possible. Hypertension often runs in families, indicating that genetic factors may play an 
important role in the development of essential hypertension. Data suggest that there are 
monogenic and polygenic forms of BP dysregulation that may be responsible for essential 
hypertension. Many of these genetic traits feature genes that affect sodium balance, but 
genetic mutations altering urinary kallikrein excretion, nitric oxide release, aldosterone 
excretion, other adrenal steroids, and angiotensinogen are also documented.
20 
1.2.2 Secondary hypertension 
Some additional signs and symptoms may suggest secondary hypertension, i.e. hypertension 
due to an identifiable cause such as kidney diseases or endocrine diseases. For example, 
truncal obesity, glucose intolerance, moon face, a "buffalo hump" and purple stretch marks 
suggest Cushing's syndrome.
[5]
 Thyroid disease and acromegaly can also cause hypertension 
and have characteristic symptoms and signs.
[5]
 An abdominal bruit may be an indicator of 
renal artery stenosis (a narrowing of the arteries supplying the kidneys), while decreased 
blood pressure in the lower extremities and/or delayed or absent femoral arterial pulses may 
indicate aortic coarctation (a narrowing of the aorta shortly after it leaves the heart). Labile or 
paroxysmal hypertension accompanied by headache, palpitations, pallor, and perspiration 
should prompt suspicions of pheochromocytoma.
[5]
 
Hypertensive crisis 
Severely elevated blood pressure (equal to or greater than a systolic 180 or diastolic of 
110 — sometimes termed malignant or accelerated hypertension) is referred to as a 
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"hypertensive crisis", as blood pressures above these levels are known to confer a high risk of 
complications. People with blood pressures in this range may have no symptoms, but are 
more likely to report headaches (22% of cases)
[6]
 and dizziness than the general population.
[2]
 
Other symptoms accompanying a hypertensive crisis may include visual deterioration or 
breathlessness due to heart failure or a general feeling of malaise due to renal failure.
[5]
 Most 
people with a hypertensive crisis are known to have elevated blood pressure, but additional 
triggers may have led to a sudden rise.
[7]
 
A "hypertensive emergency", previously "malignant hypertension", is diagnosed 
when there is evidence of direct damage to one or more organs as a result of the severely 
elevated blood pressure. This may include hypertensive encephalopathy, caused by brain 
swelling and dysfunction, and characterized by headaches and an altered level of 
consciousness (confusion or drowsiness). Retinal papilloedema and/or fundal hemorrhages 
and exudates are another sign of target organ damage. Chest pain may indicate heart muscle 
damage (which may progress to myocardial infarction) or sometimes aortic dissection, the 
tearing of the inner wall of the aorta. Breathlessness, cough, and the expectoration of blood-
stained sputum are characteristic signs of pulmonary edema, the swelling of lung tissue due 
to left ventricular failure an inability of the left ventricle of the heart to adequately pump 
blood from the lungs into the arterial system.
[7]
 Rapid deterioration of kidney function (acute 
kidney injury) and microangiopathic hemolytic anemia (destruction of blood cells) may also 
occur.
[7]
 In these situations, rapid reduction of the blood pressure is mandated to stop ongoing 
organ damage.
[7]
 In contrast there is no evidence that blood pressure needs to be lowered 
rapidly in hypertensive urgencies where there is no evidence of target organ damage and over 
aggressive reduction of blood pressure is not without risks.
[5]
 Use of oral medications to 
lower the BP gradually over 24 to 48h is advocated in hypertensive urgencies.
[7]
 
1.3 DIAGNOSIS 
 
Essential hypertension is usually asymptomatic. The primary physical finding is 
elevated BP. The diagnosis of hypertension cannot be made based on one elevated BP 
measurement. The average of two or more measurements taken during two or more clinical 
encounters should be used to diagnose hypertension.
2
 Thereafter, this BP average can be used 
to establish a diagnosis and then to classify the stage of hypertension present in the patient. 
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1.3.1 Measuring blood pressure 
 
1.3.1.1 Sphygmomanometry 
 
Indirect measurement of BP using a sphygmomanometer is a common routine 
medical screening tool that should be conducted at every health care encounter.
20 
The 
appropriate procedure to measure BP has been described by the American Heart Association 
(AHA).
22
 It is imperative that the measurement equipment (inflation cuff, stethoscope, 
manometer) meet certain national standards.
23
 These standards use criteria to ensure 
maximum quality and precision with measurement. 
 
1.4. PATHOPHYSIOLOGY
20,24 
 
A clear understanding of arterial BP and regulation is needed to manage hypertension 
appropriately and to understand antihypertensive drug therapy mechanistically. Multiple 
factors that control BP are potential contributing components in the development of 
hypertension. These include malfunctions in either humoral (i.e., the renin-angiotensin-
aldosterone system [RAAS]) or vasodepressor mechanisms, abnormal neuronal mechanisms, 
defects in peripheral autoregulation, and disturbances in sodium, calcium, and natriuretic 
hormone. Many of these factors are cumulatively affected by the multifaceted RAAS, which 
ultimately regulates arterial BP. 
  
1.4.1 Potential mechanisms of pathogenesis 
 
Blood pressure is the mathematical product of cardiac output and peripheral 
resistance. Increased blood pressure can result from increased cardiac output and/or increased 
total peripheral resistance. 
 
 
 
 
 
 
Dept.of Pharmacy Practice, JKKN, Komarapalayam Page 10 
 
 
Table.3 
 
Increased cardiac output Increased peripheral resistance 
Increased cardiac preload: 
 Increased fluid volume from excess 
sodium intake or renal  sodium 
retention (from reduced number of 
nephrons or decreased glomerular 
filtration) 
Venous constriction: 
 Excess stimulation of the RAAS 
 Sympathetic nervous system 
overactivity 
Functional vascular constriction: 
 Excess stimulation of the RAAS 
 Sympathetic nervous system 
overactivity 
 Genetic alterations of cell membranes 
 Endothelial-derived factors 
Structural vascular hypertrophy: 
 Excess stimulation of the RAAS 
 Sympathetic nervous system 
overactivity 
 Genetic alterations of cell membranes 
 Endothelial-derived factors 
 Hyperinsulinemia resulting from 
obesity or  the metabolic syndrome 
 
1.4.2 Humoral mechanisms 
 
 Several humoral abnormalities may be involved in the development of essential 
hypertension. These abnormalities may involve the the renin-angiotensin-aldosterone system, 
natriuretic hormone and hyperinsulinemia. 
 
1.4.2.1 The renin-angiotensin-aldosterone system (RAAS) 
 
The RAAS is a complex endogenous system that is involved with most regulatory 
components of arterial BP. Activation and regulation are governed primarily by the kidney. 
The RAAS regulates sodium, potassium, and fluid balance. Therefore, this system 
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significantly influences vascular tone and sympathetic nervous system activity and is the 
most influential contributor to the homeostatic regulation of BP. Renin is an enzyme that is 
stored in the juxtaglomerular cells, which are located in the afferent arterioles of the kidney. 
The release of renin is modulated by several factors: intrarenal factors (e.g., renal perfusion 
pressure, catecholamines, and angiotensin II) and extrarenal factors (e.g., sodium, chloride, 
and potassium). 
 
Renin catalyzes the conversion of angiotensinogen to angiotensin I in the blood. 
Angiotensin I is then converted to angiotensin II by angiotensin-converting enzyme (ACE). 
After binding to specific receptors (classified as either AT1 or AT2 subtypes), angiotensin II 
exerts biologic effects in several tissues. The AT1 receptor is located in brain, kidney, 
myocardium, peripheral vasculature, and the adrenal glands. These receptors mediate most 
responses that are critical to cardiovascular and kidney function. The AT2 receptor is located 
in adrenal medullary tissue, uterus, and brain. Stimulation of the AT2 receptor does not 
influence BP regulation. Circulating angiotensin II can elevate BP through pressor and 
volume effects. The pressor effects include direct vasoconstriction, stimulation of 
catecholamine release from the adrenal medulla, and centrally mediated increases in 
sympathetic nervous system activity. Angiotensin II also stimulates aldosterone synthesis 
from the adrenal cortex. This leads to sodium and water reabsorption that increases plasma 
volume, total peripheral resistance, and ultimately, BP. 
 
1.4.2.2 Natriuretic hormone 
 
Natriuretic hormone inhibits sodium and potassium ATPase and thus interferes with 
sodium transport across cell membranes. Inherited defects in the kidney’s ability to eliminate 
sodium can cause an increased blood volume. A compensatory increase in the concentration 
of circulating natriuretic hormone theoretically could increase urinary excretion of sodium 
and water. However, this same hormone is also thought to block the active transport of 
sodium out of arteriolar smooth muscle cells. The increased intracellular concentration of 
sodium ultimately would increase vascular tone and BP. 
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1.4.2.3 Insulin resistance and hyperinsulinemia 
 
Increased insulin concentrations may lead to hypertension because of increased renal 
sodium retention and enhanced sympathetic nervous system activity. Moreover, insulin has 
growth hormone–like actions that can induce hypertrophy of vascular smooth muscle cells. 
Insulin also may elevate BP by increasing intracellular calcium, which leads to increased 
vascular resistance. The exact mechanism by which insulin resistance and hyperinsulinemia 
occur in hypertension is unknown. However, this association is strong because many of the 
criteria used to define this population (elevated blood pressure, obesity, dyslipidemia, and 
elevated blood glucose) are often present in hypertensive patients.
20
 
 
1.4.3 Neuronal regulation 
  
 The central and autonomic nervous systems are intricately involved in the regulation 
of arterial BP. A number of receptors that either enhance or inhibit norepinephrine release are 
located on the presynaptic surface of sympathetic terminals. The  and  presynaptic 
receptors play a role in negative and positive feedback to the norepinephrine containing 
vesicles located near the neuronal ending. Stimulation of presynaptic -receptors (2) exerts 
a negative inhibition on norepinephrine release. Stimulation of presynaptic -receptors 
facilitates further release of norepinephrine. Sympathetic neuronal fibers located on the 
surface of effector cells innervate -receptors (2). Stimulation of postsynaptic -receptors 
(2) on arterioles and venules results in vasoconstriction. There are two types postsynaptic -
receptors, 1 and 2.. Both are present in all tissue innervated by the sympathetic nervous 
system. However, in some tissues, 1-receptors predominate, and in other tissues, 2-
receptors predominate. Stimulation of 1-receptors in the heart results in an increase in heart 
rate and contractility, whereas stimulation of 2-receptors in the arterioles and venules causes 
vasodilation. 
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1.4.4 Peripheral autoregulatory components 
 
Abnormalities in renal or tissue autoregulatory systems could cause hypertension. It is 
possible that a renal defect in sodium excretion may develop first, which can then cause 
resetting of tissue autoregulatory processes, resulting in a higher arterial BP. The kidney 
usually maintains normal BP through a volume-pressure–adaptive mechanism. When BP 
drops, the kidneys respond by increasing retention of sodium and water. These changes lead 
to plasma volume expansion, which increases BP. Conversely, when BP rises above normal, 
renal sodium and water excretion are increased to reduce plasma volume and cardiac output. 
This ultimately will maintain homeostatic BP conditions. 
 
1.4.5 Vascular endothelial mechanisms 
 
Vascular endothelium and smooth muscle play important roles in regulating blood 
vessel tone and BP. These regulating functions are mediated through vasoactive substances 
that are synthesized by endothelial cells. It has been postulated that a deficiency in the local 
synthesis of vasodialating substances (e.g., prostacyclin and bradykinin) or excess 
vasoconstricting substances (e.g., angiotensin II and endothelin I) contribute to essential 
hypertension, atherosclerosis, and other diseases. Nitric oxide is produced in the endothelium, 
relaxes the vascular epithelium, and is a very potent vasodilator. The nitric oxide system is an 
important regulator of arterial BP. Hypertensive patients may have an intrinsic deficiency in 
nitric oxide release, resulting in inadequate vasodilatation. Although the exact role of nitric 
oxide in hypertension is unclear, it may be a pharmacologic target in the future. 
 
1.4.6 Electrolytes and other chemicals 
 
Epidemiologic and clinical data have associated excess sodium intake with 
hypertension. Population-based studies indicate that high-salt diets are associated with a high 
prevalence of stroke and hypertension. Conversely, low-salt diets are associated with a low 
prevalence of hypertension. Clinical studies have shown consistently that dietary sodium 
restriction lowers BP in many (but not all) patients with elevated BP. 
         Altered calcium homeostasis also may play an important role in the pathogenesis of 
hypertension. A lack of dietary calcium hypothetically can disturb the balance between 
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intracellular and extracellular calcium, resulting in an increased intracellular calcium 
concentration. This imbalance can alter vascular smooth muscle function by increasing 
peripheral vascular resistance. 
 
          In the case of potassium, Potassium depletion may increase peripheral vascular 
resistance, but the clinical significance of small serum potassium concentration changes is 
unclear. Furthermore, data demonstrating reduced cardiovascular risk with dietary potassium 
supplementation are very limited. 
 
1.5. TREATMENT
20 
  
1.5.1 Goal of therapy 
 
 The overall goal of treating hypertension is to reduce hypertension-associated 
morbidity and mortality.
2
 This morbidity and mortality are related to target-organ damage 
(e.g., cardiovascular events, cerebrovascular events, heart failure, and kidney disease). 
Reducing risk remains the primary purpose of hypertension therapy, and the choice of drug 
therapy is influenced significantly by evidence demonstrating such risk reduction. 
  
1.5.2 General approach to treatment 
 
Hypertension is one of the most common medical conditions, BP control rates are 
poor. Many hypertensive patients are at goal DBP values but continue to have elevated SBP 
values. It has been estimated that of the hypertensive population that is treated yet not 
controlled, 76.9% have an SBP greater than or equal to 140 mm Hg with DBP values less 
than 90 mm Hg.
25
 
 
The diaganosed patient should be placed on both lifestyle modifications and drug 
therapy concurrently. Lifestyle modification alone is considered appropriate therapy for 
patients with prehypertension. However, lifestyle modifications alone are not considered 
adequate for patients with hypertension or patients with BP goals of less than 130/80 mm Hg 
(those with diabetes and chronic kidney disease) who have BP values above their goal. 
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1.5.3 Nonpharmacologic therapy 
 
All patients with prehypertension and hypertension should be prescribed lifestyle 
modifications. These approaches are recommended by the JNC7
2
 and provide small to 
moderate reductions in SBP. Aside from lowering BP in patients with known hypertension, 
lifestyle modification can decrease the progression to hypertension in patients with 
prehypertension BP values.
26
 In a number of hypertensive patients with relatively good BP 
control while on single antihypertensive drug therapy, sodium reduction and weight loss may 
allow withdrawal of drug therapy.
27,28
 
 
 A sensible dietary program is one that is designed to reduce weight gradually for 
overweight and obese patients and one that restricts sodium intake with only moderate 
alcohol consumption. Successful implementation of dietary lifestyle modifications by 
clinicians requires aggressive promotion through reasonable patient education, 
encouragement, and continued reinforcement. Patients may better understand the rationale for 
dietary intervention in hypertension if they are provided the following observations and facts: 
1. Hypertension is two to three times more prevalent in overweight as compared with 
lean persons. 
2. Over 60% of hypertensive persons are overweight. 
3. Weight loss, even as little as 10 pounds, can decrease BP significantly in hypertensive 
overweight individuals.
29
 
4. Abdominal obesity is associated with the metabolic syndrome, which is a precursor to 
hypertension and insulin-resistance syndrome that may progress to type 2 diabetes, 
dyslipidemia, and ultimately, cardiovascular disease.
30
 
5. Diets rich in fruits and vegetables and low in saturated fat have been shown to lower 
BP in hypertensive individuals.
31,32
 
6. Although some hypertensive patients are not salt-sensitive, most people experience 
some degree of SBP reduction with sodium restriction.
20,33
 
 
A controlled diet plan is needed
  
that is rich in fruits, vegetables, and low-fat dairy 
products with a reduced content of saturated and total fat. The recommended restriction is 
less than 2.4 g (100 mEq) sodium per day. Patients should be aware of the multiple sources of 
dietary sodium (e.g., processed meats, soups, and table salt) so that they may follow this 
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restriction. Excessive alcohol use can either cause or worsen hypertension. Carefully 
designed programs of physical activity can lower BP. Regular aerobic exercise for at least 30 
minutes a day most days of the week is ideal for most patients.
 
 
1.5.4 Pharmacologic therapy 
 
There are nine different antihypertensive drug classes. Diuretics, -blockers, ACE 
inhibitors, angiotensin II receptor blockers, and calcium channel blockers are considered 
primary antihypertensive agents. These agents, either alone or in combination, should be used 
to treat the majority of hypertensive patients because evidence from outcomes data have 
demonstrated benefits with these classes. Several of these classes (i.e., diuretics, -blockers, 
and calcium channel blockers) have subclasses where significant differences in mechanism of 
action, clinical use, or side effects or evidence from outcomes studies exist. -Blockers, 
central 2-agonists, adrenergic inhibitors, and vasodilators are considered alternative drug 
classes that may be used in select patients after primary agents. 
 
According to JNC7 guidelines thiazide-type diuretics whenever possible as first-line 
therapy for most patients.
2
 This recommendation is specifically for those without compelling 
indications and is based on the best available evidence demonstrating reductions in morbidity 
and mortality. However, diuretics are also useful agents in hypertensive patients with 
compelling indications, but they are not always the first agent recommended based on the 
compelling indication present. 
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Table.4 Primary antihypertensive agents 
 
Class Subclass Drug 
Usual Dose  
Range, 
mg/day 
Diuretics 
Thiazides 
Chlorthalidone 6.25–25 
Hydrochlorothiazide 12.5–50 
Indapamide 1.25–2.5 
Metolazone 0.5 
Loop diuretics 
Loops Bumetanide 0.5–4 
Furosemide 20–80 
Torsemide 5 
Potassium sparing 
Amiloride 5–10 
Amiloride/ 
Hydrochlorothiazide 
 
5–10/50–100 
 
Triamterene 50–100 
Triamterene/ 
Hydrochlorothiazide 
37.5–75/25–
50 
Aldosterone 
Antagonists 
Eplerenone 50–100 
Spironolactone 25–50 
Spironolactone/ 
Hydrochlorothiazide 
25–50/25–50 
Angiotensin converting enzyme 
inhibitors 
Benazepril 10–40 
Captopril 12.5–150 
Enalapril 5–40 
Fosinopril 10–40 
Lisinopri 10–40 
Moexipril 7.5–30 
Perindopril 4–16 
Quinapril 10–80 
Ramipril 2.5–10 
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Trandolapril 1–4 
Angiotensin II receptor Blockers 
Candesartan 8–32 
Eprosartan 600–800 
Irbesartan 150–300 
Losartan 50–100 
Olmesartan 20–40 
Telmisartan 20–80 
Valsartan 80–320 
β-Blockers 
Cardioselective 
Atenolol 25–100 
Betaxolol 5–20 
Bisoprolol 2.5–10 
Metoprolol 50–200 
Nebivolol 2.5-5 
Nonselective 
Nadolol 40–120 
Propranolol 80–320 
Timolol 10–40 
Intrinsic 
sympathomimetic 
activity 
Acebutolol 200–800 
Carteolol 2.5–10 
Penbutolol 10–40 
Pindolol 10–60 
Mixed - and 
-blockers 
Carvedilol 12.5–50 
Labetolol 200–800 
Calcium channel 
blockers 
Dihydropyridines 
Amlodipine 2.5–10 
Felodipine 5–20 
Isradipine 5–10 
Nicardipine 60–120 
Nifedipine 30–90 
Nisoldipine 10–40 
Non-
Dihydropyridines 
Diltiazem 180–360 
Verapamil 180–480 
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Table.5 Alternative antihypertensive agents 
 
Class Drug 
Usual Dose  
Range, 
mg/day 
α1-Blockers 
Doxazosin 1–8 
Prazosin 2–20 
Terazosin 1–20 
Central α 2-agonists 
Clonidine 0.1–0.8 
Methyldopa 250–1000 
Peripheral adrenergic antagonist Reserpine 0.05–0.25 
Direct arterial vasodilators 
Minoxidil 10–40 
Hydralazine 20–100 
 
1.5.4.1 Individual antihypertensive agents
2,29,34 
 
 Diuretics 
 
Diuretics, preferably a thiazide, are fist-line agents for most patients with 
hypertension.
 
Moreover, when combination therapy is needed in hypertension to control BP, 
a diuretic is recommended as
 
one of the agents used.
2 
Four subclasses of diuretics are used in 
the treatment of hypertension: thiazides, loop diuretics, potassium-sparing agents, and 
aldosterone antagonists Thiazide diuretics have additional actions that may further explain 
their antihypertensive effects. Thiazides mobilize sodium and water from arteriolar walls. 
This effect would lessen the amount of physical encroachment on the lumen of the vessel 
created by excessive accumulation of intracellular fluid. As the diameter of the lumen relaxes 
and increases, there is less resistance to the flow of blood, and peripheral vascular resistance 
drops further. Thiazides also are postulated to cause direct relaxation of vascular smooth 
muscle. 
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Angiotensin-converting enzyme inhibitors (ACEI) 
 
ACE inhibitors are considered second-line therapy to diuretics in most patients with 
hypertension.
2
 ACE inhibitors have many roles for patients with hypertension and coexisting 
conditions. ACE facilitates the production of angiotensin II, which has a major role in the 
regulation of arterial BP. ACE is distributed in many tissues and is present in several different 
cell types, but its principal location is in endothelial cells. Therefore, the major site for 
angiotensin II production is in the blood vessels, not the kidney. ACE inhibitors block the 
conversion of angiotensin I to angiotensin II. This latter substance is a potent vasoconstrictor 
that also stimulates aldosterone secretion. ACE inhibitors also block the degradation of 
bradykinin and stimulate the synthesis of other vasodilating substances, including 
prostaglandin and prostacyclin. The observation that ACE inhibitors lower BP in patients 
with normal plasma rennin activity suggests that bradykinin and perhaps tissue production of 
ACE are important in hypertension. Increased bradykinin enhances the BP-lowering effects 
of ACE inhibitors. 
 
Angiotensin II receptor blockers 
 
Angiotensin II is generated by two enzymatic pathways: the RAAS, which involves 
ACE, and an alternative pathway that uses other enzymes such as chymases. ACE inhibitors 
inhibit only the effects of angiotensin II produced through the RAAS, whereas ARBs inhibit 
angiotensin II from all pathways. It is unclear howthese differences affect tissue 
concentrations of ACE. Because of these differences, ACE inhibitors only partially block the 
effects of angiotensin II. ARBs directly block the angiotensin II type 1 (AT1) receptor that 
mediates the known effects of angiotensin II in humans: vasoconstriction, aldosterone 
release, sympathetic activation, antidiuretic hormone release, and constriction of the efferent 
arterioles of the glomerulus. They do not block the angiotensin II type 2 (AT2) receptor. 
Therefore, beneficial effects of AT2 receptor stimulation (i.e., vasodilation, tissue repair, and 
inhibition of cell growth) remain intact when ARBs are used. Unlike ACE inhibitors, ARBs 
do not block the breakdown of bradykinin. Therefore, some of the beneficial effects of 
bradykinin such as vasodilation (which can enhance BP lowering), regression of myocyte 
hypertrophy and fibrosis, and increased levels of tissue plasminogen activator are not present 
with ARB therapy. 
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Calcium channel blockers (CCB) 
 
CCBs are not first-line agents but are very effective antihypertensive agents, 
especially in African-American patients. They have compelling indications in high coronary 
disease risk and in diabetes. However, with these compelling indications, they are in addition 
to or in replacement of other antihypertensive drug classes. Some data indicated that 
dihydropyridines may not provide as much protection against cardiac events when compared 
with ―conventional‖ therapy (diuretics and β-blockers) or ACE inhibitors in uncomplicated 
hypertension.
35
 Contraction of cardiac and smooth muscle cells requires an increase in free 
intracellular calcium concentrations from the extracellular fluid. When cardiac or vascular 
smooth muscle is stimulated, voltage-sensitive channels in the cell membrane are opened, 
allowing calcium to enter the cells. The influx of extracellular calcium into the cell releases 
stored calcium from the sarcoplasmic reticulum. As intracellular free calcium concentration 
increases, it binds to a protein, calmodulin, which then activates myosin kinase, enabling 
myosin to interact with actin to induce contraction. CCBs work by inhibiting influx of 
calcium across the cell membrane. There are two types of voltage-gated calcium channels: a 
high-voltage channel (L-type) and a low-voltage channel (T-type). Currently available CCBs 
only block the L-type channel, which leads to coronary and peripheral vasodilation. 
 
β-blockers 
 
β -Blockers have been used in several large outcome trials in hypertension.  Several 
mechanisms of action have been proposed for β -adrenoceptor blockers (β -blockers), but 
none of them alone has been shown to be associated consistently with a reduction in arterial 
BP. β-Blockers have negative chronotropic and inotropic cardiac effects that reduce cardiac 
output, which explains some of the antihypertensive effect. However, cardiac output falls 
equally in patients treated with β-blockers regardless of BP lowering. β-Blockers that possess 
a greater affinity for β1-receptors than β2-receptors are cardioselective. Both β1- and β 2-
adrenoceptors are distributed throughout the body, but they concentrate differently in certain 
organs and tissues. There is a preponderance of β 1- ceptors in the heart and kidney and a 
preponderance of β 2-receptors in the lungs, liver, pancreas, and arteriolar smooth muscle. β 
1-Receptor stimuation increases heart rate, contractility, and renin release. β 2-Receptor 
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stimulation results in bronchodilation and vasodilation. Cardioselective β -blockers are less 
likely to provoke bronchospasm and vasoconstriction. 
 
α 1-Blockers 
 
They work in the peripheral vasculature and inhibit the uptake of catecholamines in 
smooth muscle cells, resulting in vasodilation and BP lowering. 
 
Central α 2-agonists 
 
These agents lower BP primarily by stimulating α 2-adrenergic receptors in the brain. 
This stimulation reduces sympathetic outflow from the vasomotor center in the brain and 
increases vagal tone. It is also believed that peripheral stimulation of presynaptic α 2-
receptors may further reduce sympathetic tone. Reduced sympathetic activity, together with 
enhanced parasympathetic activity, can decrease heart rate, cardiac output, total peripheral 
resistance, plasma renin activity, and baroreceptor reflexes. 
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1.6 DRUG UTILIZATION STUDIES
36 
 
Drug utilization research was defined by WHO as ―the marketing, distribution, 
prescription, and use of drugs in a society, with special emphasis on the resulting medical, 
social and economic consequences‖.37 
 
Studies on the process of drug utilization focus on the factors related to the 
prescribing, dispensing, administering, and taking of medication, and its associated events, 
covering the medical and non-medical determinants of drug utilization, the effects of drug 
utilization, as well as studies of how drug utilization relates to the effects of drug use, 
beneficial or adverse.
38,39
 The therapeutic practice is expected to be primarily based on 
evidence provided by pre marketing clinical trials, but complementary data from post 
marketing period are needed to provide an adequate basis for improving drug therapy.
40
 
  
1.6.1 Pharmacoepidemiology  
 
Pharmacoepidemiology applies epidemiological methods to studies of the clinical use 
of drugs in populations. A modern definition of pharmacoepidemiology is: ―the study of the 
use and effects/side-effects of drugs in large numbers of people with the purpose of 
supporting the rational and cost-effective use of drugs in the population thereby improving 
health outcomes‖. 
 
Pharmacoepidemiology may be drug-oriented, emphasizing the safety and 
effectiveness of individual drugs or groups of drugs, or utilization oriented aiming to improve 
the quality of drug therapy through pedagogic (educational) intervention. Drug utilization 
research may also be divided into descriptive and analytical studies. The emphasis of the 
former has been to describe patterns of drug utilization and to identify problems deserving 
more detailed studies. Analytical studies try to link data on drug utilization to figures on 
morbidity, outcome of treatment and quality of care with the ultimate goal of assessing 
whether drug therapy is rational or not. Sophisticated utilization-oriented 
pharmacoepidemiology may focus on the drug (e.g. dose-effect and concentration-effect 
relationships), the prescriber (e.g. quality indices of the prescription), or the patient (e.g. 
selection of drug and dose, and comparisons of kidney function, drug metabolic 
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phenotype/genotype, age, etc.).Drug utilization research is thus an essential part of 
pharmacoepidemiology as it describes the extent, nature and determinants of drug exposure. 
   
1.6.2 Scope of drug utilization studies 
 
Drug utilization studies may include descriptive epidemiological approaches to the 
study of drug utilization, but also the assessment of how drug utilization relates to the effects 
of drug use, beneficial or adverse. The research in this field aims to analyse the present state 
and the developmental trends, of drug usage at various levels of the health care system, 
whether national, regional, local or institutional. Drug utilization studies may evaluate drug 
use at a population level, according to age, sex, social class, morbidity, among other 
characteristics. These studies are useful to provide denominators to calculate rates of reported 
adverse drug reactions, to monitor the utilization of drugs from therapeutic categories where 
particular problems can be anticipated (e.g., narcotic analgesics, hypnotics and sedatives, and 
other psychotropic drugs), to monitor the effects of informational and regulatory activities 
(e.g., adverse events alerts, monitoring urgent safety restrictions). Drug utilization data may 
me used to produce crude estimates of disease prevalence (e.g., cardiovascular disease, 
antidiabetic drugs, to plan drug importation, production, and distribution, and to estimate 
drug expenditures. 
 
The characterization of drug utilization may be extended linking prescription data to 
the reasons for the drug prescribing. They include the concept of appropriateness that must be 
assessed relative to indication for treatment, concomitant diseases (that might contraindicate 
or interfere with chosen therapy) and the use of other drugs (interactions). Therefore they can 
document the extent of inappropriate prescribing of drugs (e.g. antibiotics, NSAIDs) and 
even the associated adverse clinical, ecological, and economic consequences. Moreover, they 
can also explore the percentage of drugs that adhere to the evidence-based recommendations 
in place for its indications. 
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1.6.3 Importance of drug utilization studies 
 
The principal aim of drug utilization research is to facilitate rational use of drugs in 
populations. For the individual patient rational use of a drug implies the prescription of a 
well-documented drug in an optimal dose on the right indication, with the correct information 
and at an affordable price. Without knowledge on how drugs are being prescribed and used, it 
is difficult to initiate a discussion on rational drug use and to suggest measures to change 
prescribing habits for the better. Information on the past performance of prescribers is the 
linchpin of any auditing system. 
 
Drug utilization research in itself does not necessarily provide answers, but it 
contributes to rational drug use in three important ways: 
   
1.6.3.1 Description of drug use patterns 
 
Drug utilization research will increase our understanding of how drugs are being used 
by: 
a. Making estimates of the numbers of patients exposed to drugs within a given time 
period. Such estimates may either refer to all drug users, regardless of when they 
started to use the drug (prevalence), or focus on patients who started to use the drug 
within the selected period (incidence). 
b. Describing the extent of use at a certain moment and/or in a certain area (e.g. country, 
region, community, hospital). Such descriptions are most meaningful when they are 
part of a continuous evaluation system, i.e. when the patterns are followed over time 
and trends in drug use can be described. 
c. Estimating (e.g. on the basis of epidemiological data on a disease) to what extent 
drugs are properly used, overused, or underused. 
d. Describing the pattern or profile of drug use - assessing which alternative drugs are 
being used for particular conditions and to what extent. 
e. Comparing observed patterns of drug use with current recommendations or guidelines 
for the treatment of a certain disease. 
f. Applying quality indicators to drug utilization patterns. An example is the so-called 
DU90% (drug utilization 90%), a further development of the ―Top-10‖ list. The 
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DU90% segment reflects the number of drugs that account for 90% of drug 
prescriptions and adherence to local or national prescription guidelines in this 
segment. This general indicator can be applied at different levels (individual 
prescriber, group of prescribers, hospitals, region, county, etc.) to get a rough estimate 
of the quality of prescribing. 
g. Feeding back drug utilization data to prescribers. This is particularly useful when the 
individual’s drug prescribing can be compared with some form of "gold standard" or 
best practice, and with the average prescriptions in the country or the area. 
h. Relating the number of case reports about a drug problem or adverse effects to the 
number of patients exposed in order to assess the potential magnitude of the problem. 
If it is possible to detect that the reaction is more common in a certain age group, in 
certain conditions or at a special dose level, improving the information on proper use 
such as indications, contraindications and appropriate dosages may be sufficient to 
assure a safer use. Thereby withdrawal of the drug from the market may be avoided. 
  
1.6.3.2 Early signals of irrational use of drugs 
 
Drug utilization research may generate hypotheses that set the agenda for further 
investigations by: 
 
a. Comparing drug utilization patterns and costs between different regions or time 
periods. Hypotheses can be generated to form the basis for investigations of the 
reasons for, and health implications of, the differences found. Geographical 
differences and changes overtime in drug use may have medical, social and economic 
implications both for the individual patient and for society, and are thus important to 
identify, explain and sometimes correct. 
b. Comparing observed patterns of drug use with current recommendations guidelines for 
the treatment of a certain disease. Hypotheses can then be generated about whether 
discrepancies represent less than optimal practice, whether pedagogic interventions 
(education) are required, or whether the guidelines need to be reviewed in the light of 
actual practice. These considerations should include both underuse and overuse of 
drugs. 
 
Dept.of Pharmacy Practice, JKKN, Komarapalayam Page 27 
 
 
1.6.3.3 Interventions to improve drug use – follow-up 
 
Drug utilization research may enable us to assess whether interventions undertaken to 
improved drug use have had the desired impact by: 
a. Monitoring and evaluating the effects of measures taken to improve undesirable 
patterns of drug use (regional formularies, information, regulatory policies, etc.) 
b. Following the impact of regulatory changes or changes in insurance or reimbursement 
systems. This also requires a broad survey, because the total cost to society may 
remain the same or may even increase, if other more expensive drugs are used as an 
alternative. 
c. Assessing to which extent promotional activities of the pharmaceutical industry and 
educational activities of the society impact on the patterns of drug use. 
 
1.6.4 Types of drug use informations 
 
Different types of drug use information are required depending on the problem being 
evaluated. These include information about the overall drug use, or use of drug groups, 
individual generic compounds or specific products. Often, information about the condition 
being treated, about the patient and about the prescriber will be required. In addition, data on 
drug costs will be important in ensuring that drugs are used efficiently and economically. 
These types of drug information are described below. 
  
1.6.4.1 Drug based information 
 
The trends in total drug use may sometimes be useful to know, but more detailed 
information is usually required to answer clinically important questions. This may involve 
aggregation of drug use at various levels, and information on indications, doses and dosage 
regimens. 
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1.6.4.2 Problem or encounter-based information 
 
Instead of asking how a particular group of drugs is used, one may well address the 
question how a particular problem (e.g. sore throat, hypertension, gastric ulcer, depression) is 
managed. 
   
1.6.4.3 Patient information 
 
Demographic and other information about the patient will often be useful. The age 
distribution of patients will sometimes be of critical importance, for example to assess the 
likelihood of severe adverse effects with NSAIDs, or whether the drug is being used in an age 
group different to that in which theclinical trials were performed. The co-morbidities of the 
patient group may be important in determining treatment choice and adverse effects. As an 
example in the management of hypertension, beta-blockers should be avoided in patients with 
asthma, and ACE inhibitors preferred in patients with heart failure. Qualitative information 
such as knowledge, beliefs, and perceptions among patients and their attitudes to drugs will 
be important in some cases, for example in assessing patient pressures on doctors to prescribe 
antibiotics, or in designing consumer information/education programs. 
 
1.6.4.4 Prescriber information 
 
The prescriber is a critical point in determining drug use. Some sceptics even claim 
that doctors differ more than patients and that differences in drug prescribing often lack 
rational explanations. Dissecting the factors that determine prescribing behaviour is therefore 
often central to understanding how and why drugs are prescribed. 
 
1.6.5 Types of drug utilization study 
 
Drug utilization studies can be targeted towards any of the following links in the drug-use 
chain: 
 The systems and structures surrounding drug use (e.g. how drugs are ordered, 
delivered and administered in a hospital or health care facility). 
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 the processes of drug use (e.g. what drugs are used and how they are used and does 
their use comply with the relevant criteria, guidelines or restrictions); and 
 The outcomes of drug use (e.g. efficacy, adverse drug reactions and the use of 
resources such as drugs, laboratory tests, hospital beds or procedures). 
 
 
1.6.5.1 Cross-sectional studies 
 
Cross-sectional data provide a «snapshot» of drug use at a particular time (e.g. over a 
year, a month or a day). Such studies might be used for making comparisons with similar data 
collected over the same period in a different country, health facility or ward, and could be 
drug-, problem-, indication, prescriber- or patient-based. Alternatively, a cross-sectional 
study can be carried out before and after an educational or other intervention. Studies can 
simply measure drug use, or can be criterion-based to assess drug use in relation to guidelines 
or restrictions. 
 
1.6.5.2 Longitudinal studies 
 
Public health authorities are often interested in trends in drug use, and longitudinal 
data are required for this purpose. Drug-based longitudinal data can be on total drug use as 
obtained through a claims database, or the data may be based on a statistically valid sample 
of pharmacies or medical practices. Longitudinal data are often obtained from repeated cross-
sectional surveys (e.g. IMS (Intercontinental Medical Statistics) practice-based data are of 
this type).Data collection is continuous, but the practitioners surveyed, and therefore the 
patients, are continually changing. Such data give information about overall trends, but not 
about prescribing trends for individual practitioners or practices. 
 
1.6.5.3 Continuous longitudinal studies 
 
In some cases continuous longitudinal data at the individual practitioner and patient 
level can be obtained. Claims databases are often able to follow individual patients using a 
unique (but anonymous) identifier. These data can provide information about concordance 
with treatment based on the period between prescriptions, coprescribing and duration of 
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treatment. As electronic prescribing becomes more common, databases are being developed 
to provide Continuous longitudinal data comprising full medical and prescribing information 
at the individual patient level. Such databases are very powerful, and can address a range of 
issues including reasons for changes in therapy, adverse effects and health outcomes. 
 
1.6.6 Sources of data on drug utilization 
 
The drug-use chain includes the processes of drug acquisition, storage, distribution, 
prescribing, patient compliance and the review of outcome of treatment. Each of these events 
is an important aspect of drug utilization, and most countries have regulations to cover these 
aspects. Data are collected, or are available, at national, regional and local health facility or 
household level and may be derived from quantitative or qualitative studies. 
 
Quantitative data may be used to describe the present situation and the trends in drug 
prescribing and drug use at various levels of the health care system. Quantitative data may be 
routinely collected data or obtained from surveys.   
 
Qualitative studies assess the appropriateness of drug utilization and generally link 
prescribing data to reasons (indications) for prescribing. Such studies have been referred to as 
―dug utilization review‖ or ―dug utilization evaluation‖  
   
1.6.6.1 Large databases 
 
The increasing interest in efficient use of health care resources has resulted in the 
establishment of computer databases for studies on drug utilization. Some of the databases 
can generate statistics for movement at various levels of the drug distribution chain, 
pharmaceutical and medical billing data or samples of prescriptions. Data may also be 
obtained from drug importers, wholesalers or local manufacturers. Data from medical 
practices and health facilities may be used to measure specific aspects of health provision and 
drug use. Such data may be used to generate indicators that provide information on 
prescribing habits and aspects of patient care. These indicators can be used to determine 
where drug use problems exist, provide a mechanism for monitoring and supervision and 
motivate health care providers to follow established health care standards. 
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1.6.6.1 Data from drug regulatory agencies 
 
Drug regulatory agencies have the legal responsibility of ensuring the availability of 
safe, efficacious and good-quality drugs in their country. They are thus the repositories of 
data on which drugs have been registered for use, withdrawn or banned within a country. 
Regulatory agencies also have inspection and enforcement functions, and are responsible for 
supervising the importation of drugs and for the issuance of permits for drug registration. It is 
possible, therefore, to obtain data on the number of drugs registered in a country from such 
agencies. Where the agency issues import permits and supervise drug importation, data on 
product type (i.e. generic or branded), volume, and port of origin, country of manufacture, 
batch number and expiry date may be collected. Where the data reflect total national imports, 
estimates of quantities of drugs in circulation can be obtained for defined periods and for 
various therapeutic groups 
  
1.6.6.3 Supplier (distribution) data 
 
Data on suppliers may be obtained from drug importers, wholesalers or local 
manufacturers. In countries where permits or licences are required from drug regulatory 
authorities and ministries of health before importation of drugs, data may be available from 
such sources. Data from these sources can generally be used to describe total quantities of 
specific drugs or drug groups, origins of supplies and type (i.e. branded or generic). 
 
1.6.6.4 Practice setting data 
 
Prescription and dispensing data are useful for determining some of the quality 
indicators of drug use recommended by WHO. These include: 
 
 Average number of drugs per prescription (encounter) 
 Percentage of drugs prescribed by generic name 
 Percentage of encounters with an antibiotic prescribed 
 Percentage of encounters with an injection prescribed 
 Percentage of drugs prescribed from essential drugs list or formulary 
 Average drug cost per encounter 
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1.6.7 Over-the-counter and pharmacist-prescribed drugs  
 
Pharmacists and other drug outlet managers may prescribe over-the-counter 
preparations or pharmacist- prepared drugs that do not require prescription by a physician. 
Data on such medications may be difficult to obtain especially in environments with weak 
drug regulation and poor record keeping, but when such information is available from stock 
or dispensing records, it broadens the understanding of drug utilization patterns. 
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2. LITERATURE REVIEW. 
 
Nazima et al.,
41
 conducted a study on Prescribing pattern in a pediatric outpatient 
department in Gujarat. The aim of the study was to find out the medicine-prescribing pattern 
in children taking treatment in pediatric out-patient department of a tertiary care teaching 
hospital in rural Gujarat. Prescriptions were collected randomly. Necessary data were 
obtained from a total of 606 prescriptions and analyzed for (i) number of medicines per 
prescription, (ii) medicines prescribed by official names, (iii) essentiality status of medicines, 
(iv) appropriateness of medicines used and that of prescriptions and (v) cost of prescription. 
The prescriptions were subjected to measuring the appropriateness of medicines by applying 
the 'appropriateness scale' to each medicine or medicine combination. The study found that 
on the basis of appropriateness scale, more than 80% prescriptions could be rated either as 
appropriate or most appropriate. Only about 1/6 of all prescriptions were found to be 
inappropriate. Considering the fact that the study was conducted in a tertiary care teaching 
institution, high proportion of appropriateness is not unexpected. We also found that more 
than 95% of total cost on account of non-essential medicines was due to prescribing of non-
essential fixed-dose drug combinations. If conscious efforts are made to curtail the use of 
non-essential fixed-dose drug combinations, one can certainly decrease this wasteful 
expenditure on medicines. The study concluded that for achieving the goal of rational use of 
medicines it is not sufficient to choose the right medicines only but also they must be 
employed in the most appropriate manner. There is an ample scope of improving the 
prescribing pattern by keeping the number of medicines as low as possible, prescribing 
medicines by official names, using medicines appropriately after selecting and consciously 
keeping the cost of therapy low. 
Rajeshwari et al,
42
 conducted a Drug Utilisation Study in Geriatric Type 2 Diabetic 
Patients. This study was aimed- to evaluate the drug utilisation pattern in geriatric T2DM 
patients. The study was conducted for a period of 6 months (July 2004 to January 2005) in an 
out-patient department of a tertiary hospital in Mangalore, Kamataka, India. The medical 
records of 64 geriatric (age >60 years) type 2 diabetic patients attending the diabetic clinic 
were reviewed. Drug prescribed mainly for DM and hypertension were included along with 
other drugs used for their comorbidities. Along with drug regimens, demographic data, age, 
and gender were recorded. The results were analysed using descriptive statistics. In elderly 
Dept.of Pharmacy Practice, JKKN, Komarapalayam Page 34 
 
 
patients with type 2 diabetes, treatment may be initiated with monotherapy, followed by early 
intervention with a combination of oral agents, including a sulphonylurea as a foundation 
insulin secretagogue in addition to a supplemental insulin sensitizer. The study also showed 
that a combination of sulphonylurea and metformin was most frequently prescribed. 
Accordingly, metformin is widely regarded as the first drug of choice for most patients with 
type 2 diabetes mellitus. The study concluded that type 2 diabetic is a progressive and 
complex disorder that is difficult to treat effectively in the long term. The ^eatment pattern 
observed in this study corroborates with the accepted pattern of treatment for DM with 
hypertension, and/or neuropathy. Metformin, glimepiride, and glibenclamide are most 
commonly prescribed OADs. Enalapril and ramipril among the ACEIs and atenolol and 
metaprolol among the beta-blockers are the frequently grescribed antihypertensives. 
Sipcic et al.
43
 conducted a study on Drug utilization patterns in Zabljak municipality, 
Serbia and Montenegro- The aim of the study was to investigate patterns of drug use in the 
semi-rural municipality of Zabljak, which could be considered a typical municipality in 
Serbia and Montenegro. The study was conducted from January to March in 2001. There was 
only one primary care health facility in Zabljak where prescribing was done, and only one 
state pharmacy, where prescribed drugs were dispensed. During the abovementioned period, 
the following data were collected from Descriptions and dispensing records: initials, sex and 
age of the patients, diagnosis, drugs dispensed, and the doses of the drugs. Drug utilization 
was calculated using the Methodology of the World Health Organization, and expressed in 
defined daily doses (DDDs) per 1000 inhabitants per day. The diagnoses were classified 
according to the tenth revision of the International Classification of Diseases. Overall drug 
utilization in Zabljak was not higher than in other countries, including developed ones. And 
also the patterns of drug utilization point to certain irrationalities. The study concluded that 
the total number of drugs utilized per 1000 inhabitants per day was within the acceptable 
range. However, the pattern of diagnosis did not correspond to the pattern of drug utilisation. 
There is a need for intervention in order to promote the rational selection and use of drugs 
among outpatients in Serbia and Montenegro.  
Jeschke et al.,
 44
 conducted a study on Evaluation of prescribing patterns in a German 
network of CAM physicians for the treatment of patients with hypertension. The study was 
aimed to investigate hypertension treatment strategies among physicians specialized in 
complementary and alternative medicine (CAM) in Germany by analysing prescribing 
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patterns and comparing these to the current treatment guidelines issued by the German 
Hypertension Society. In this prospective, multicentre observational study, which included 25 
primary care physicians specialized in CAM treatment, prescriptions and diagnoses were 
analysed for each consecutive hypertensive patient using routine electronic data. Data 
analysis was performed using univariate statistical tests (Chi square test, Cochran-Armitage 
trend test). Multiple logistic regression was used to determine factors associated with 
antihypertensive medication. Most patients were treated with conventional antihypertensive 
monotherapies. Beta-blockers were the most commonly prescribed monotherapy, followed by 
ACE inhibitors. Combination treatment usually consisted of two antihypertensive drugs 
administered either as separate agents or as a coformulation. The most common combination 
was a diuretic plus an ACE inhibitor. Patient gender, age, and comorbidities significantly 
influenced which treatment was prescribed. The study concluded as large majority of 
antihypertensive treatments prescribed by CAM physicians in the present study complied 
with the current German Hypertension Society treatment guidelines. Deviations from the 
guidelines were observed in one of every seven patients receiving some form of CAM 
treatment.  
Chantal et al
45
 conducted a study on Antihypertensive Drug Therapy in 
Saskatchewan. The aim of the study was to examine the distribution and determinants of 
patterns of use of antihypertensive agents in the first 5 years of hypertension treatment in 
Saskatchewan. Patterns of use and modifications to therapy were derived from a careful 
examination of medication use in a cohort of 19501 subjects aged 40 to 79 years, without 
recognized cardiac disease and initiating therapy with an angiotensin -converting enzyme 
inhibitor, a calcium antagonist, or a b-blocker in Saskatchewan between 1990 and 1993. 
Angiotensin-eonverting enzyme inhibitors, followed by calcium antagonists and b-blockers, 
were the most commonly prescribed agents to initiate treatment in our study population. 
Patients with diabetes were less likely to be dispensed a b-blocker, as were younger and 
female patients. Previous visits to a cardiologist decreased the likelihood of receiving 
combination therapy or angiotensin converting enzyme inhibitors but increased that of Using 
calcium antagonists. Erratic drug-taking behaviors were observed in this Saskatchewan 
population, hi addition, initial drug use does not seem to be in accordance with the stepped-
care approach to hypertension therapy recommended in the Canadian guidelines. 
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Fowad Khurshid et al.,
46
 conducted a study of  antihypertensive medication 
prescribing patterns in a university teaching hospital in south delhi, this study was aimed to  
investigate the use of antihypertensive drugs in hypertensive patients and to identify whether 
such pattern of prescription is appropriate in accordance with international guidelines for 
management of hypertension. This was a prospective analysis. A prescription based survey 
among patients with established hypertension was conducted at the Medicine Out-Patient 
Department of University Teaching Hospital in South Delhi, India. Data were collected from 
patients’ medical records as well as patients’ interviews. The study concluded that the general 
pattern of antihypertensive utilization seems to be in accordance with the international 
guidelines for management of hypertension. 
         Y.Padmanabha Reddy et a.,l
47 
 conducted a srudy of drug utilization research is defined 
as research on ―the marketing, distribution, prescription and use of drugs in a society, with 
special emphasis on the resulting medical, social and economic consequences‖ and has the 
principle aim of facilitating the rational use of drugs, our study aims to identify consumption 
and cost consumption of antihypertensive medications in secondary care hospital. It is a 
prospective study conducted for the period of 4 months. The required data were collected 
from the pharmacy from the patient case sheet or through direct patient interview by using 
suitable patient profile form, and the obtained data were evaluated in relation to the drug use. 
ATC/DDD method was used to measure the outcome variables. Antihypertensive 
consumption increased from 10826.8 DDDs in March 2011 to 16437.75 DDDs in June 2011. 
Overall, the cost consumption has been increased to12523.93 Indian rupees from the 
initiation of study period to end of the study period. Our study results shows that 
consumption and cost consumption of antihypertensive drugs were increased during the study 
period. Increased Drug use and Cost consumption of antihypertensive medications in our 
study indicates the necessity of preventive care for hypertension and patient has to be 
provided with knowledge about life style modifications in hypertension to decrease the drug 
use. This study concluded that  Drug utilization research is defined as research on ―the 
marketing, distribution, prescription and use of drugs in a society, with special emphasis on 
the resulting medical, social and economic consequences‖ and has the principle aim of 
facilitating the rational use of drugs, our study aims to identify consumption and cost 
consumption of antihypertensive medications in secondary care hospital. It is a prospective 
study conducted for the period of 4 months. The required data were collected from the 
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pharmacy from the patient case sheet or through direct patient interview by using suitable 
patient profile form, and the obtained data were evaluated in relation to the drug use. 
ATC/DDD method was used to measure the outcome variables. Antihypertensive 
consumption increased from 10826.8 DDDs in March 2011 to 16437.75 DDDs in June 2011. 
Overall, the cost consumption has been increased to12523.93 Indian rupees from the 
initiation of study period to end of the study period. Our study results shows that 
consumption and cost consumption of antihypertensive drugs were increased during the study 
period. Increased Drug use and Cost consumption of antihypertensive medications in our 
study indicates the necessity of preventive care for hypertension and patient has to be 
provided with knowledge about life style modifications in hypertension to decrease the drug 
use.. 
           Bajaj   et al.,
48
 conducted a study of prescription patterns of antihypertensive drugs 
and adherence to jnc vii guidelines in a tertiary care hospital in north india and  drug 
utilization data of 500 hypertensive patients, attending medicine Out Patient Department of 
Punjab Institute of Medical Sciences Hospital from October 2010 to March 2011 was 
collected from 24 hour hospital pharmacy. Following groups of anti hypertensive drugs were 
analyzed; Angiotensin converting enzyme inhibitors (ACE inhibitors), Angiotensin Receptor 
Blockers (ARBs), Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Alpha 
Adrenergic Blockers and Central Sympatholytics. Patients suffering from essential 
hypertension with or without other co-morbid conditions were included in the study. 
Frequency and proportion of prescribing different groups of anti hypertensive drugs as mon-
otherapy or combination therapy and prescription of fixed drug combinations (FDCs) was 
analyzed. The study concluded that the guidelines given by Joint National Committee on 
prevalence, de-tection, evaluation and treatment of high blood pressure VIIth re-port suggest 
that treatment of choice for early stage, uncomplicat-ed, essential hypertension should be 
thiazide diuretics. Presence of high risk conditions and blood pressure greater than 20/10 mm 
of Hg above normal is indication for starting therapy with drugs from other classes like ACE 
inhibitors, ARB's, beta blockers or calcium channel blockers alone or in combination with 
thiazides. Adherence to treatment guidelines can be monitored by several methods. Drug 
utilization studies are one such important method. Our data shows that JNC VII guidelines 
have been followed in totality in this study group. Thiazides are prescribed most frequently 
alone or in combi-nation with other drugs. ARB's are the most frequently prescribed group in 
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hypertensive diabetics and asthmatics as angiotensin antagonism is reported to decrease the 
onset & progress of micro-vascular complications of hypertension and diabetes mellitus [11]. 
More than half (57.4%) of patients in this study group received two or more antihypertensive 
drugs.  
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3. AIM AND OBJECTIVE OF THE STUDY 
3.1  AIM 
Hypertension is one of the major chronic diseases resulting in high mortality and 
morbidity in today`s world. A great level of attention is needed in the management of 
hypertension, because it is one of the major risk factor in the case of cardiovascular disorders. 
The prescription pattern is an important factor for the effective treatment and control the level 
of hypertension. 
A number of drugs in various combinations are generally used for effective long-term 
management of hypertension. Drug utilization studies which evaluate, analyse the medical, 
social and economic outcome of the drug therapy, are more meaningful and observe the 
prescription attitude of physicians with the aim to provide drugs rationally. The study aimed 
to assess the antihypertensive utilization pattern in hypertensive patients. 
 
3.2 OBJECTIVE 
 
1. To asses the current practice patterns in pharmacotherapy for hypertension in adult 
patients. 
2. To determine the effect of patients related variable of the treatment. 
3. To assess the disease distribution amoung the patients according to gender wise. 
4. To assess the use of monotherapy and combination therapy in treatment. 
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4. METHODOLOGY 
This study was conducted at Divine hospital, Salem, Tamil nadu from June 2013 to 
January 2014. Data was obtained from a prospective series of 310 patients of either sex by 
scrutinizing the outpatient cards and case sheets of patients attending the clinic. The protocol was 
prepared as per JNC-VII [11] guidelines. 
Inclusion criteria 
The data is collected from all the patients of either sex with primary hypertension and the 
patients without co morbid conditions in medicine outpatient department who are willing to 
participate in the study. 
Exclusion criteria 
Patients below the age of 18 years, Female patients who were pregnant, Patients who are 
not willing to participate in the study, Patients with secondary hypertension, and hypertensive 
patients with other co morbid conditions were excluded from study. 
Study procedure 
Data for present study were collected by scrutinizing the patient’s case reports, outpatient 
and inpatient cards. The data collected were analyzed for prescribing patterns of antihypertensive 
drugs and demographic profiles of the patients suffering from hypertension. 
Materials Required 
Patient data collection form 
Patient`s prescription 
Data collection parameters 
Patient demographic data 
Past medical history 
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Habits 
Physical examination findings 
Treatment given. 
Method 
Information  on patients were collected and recorded in standard proforma by reviewing 
the patient. The demographic details were collected from prescription. Diagnostic details and 
treatment were also recorded in the patient data entry form. 
Factors evaluated were: 
Patients characterstics: age,gender and demographic details. 
Co morbidities of patients 
Treatment. 
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5. RESULTS 
1. Gender wise distribution 
Figure 1 shows the gender wise distribution of the patients included in the study. The 
results revealed that out of 310 patients included the present study, 188 (60.64%) patients were 
male and 122(39.36%) were female. 
                              Table 1. Gender wise distribution of patients. 
 
GENDER NO OF PATIENTS 
(n=310) 
PERCENTAGE 
% 
Male 188 60.96 
Female 122 39.03 
 
 
Figure 1. Gender wise distribution of patients 
 
 
The maximum number of patients were in the age group of 51-60(38,71%) years, followed by age 
group 41-50(27.09%) years and 13.87% of patients in the age group of 61-70 years. 
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Table 2. Age and Gender wise distribution of patients 
 
Figure 2.Age and Gender wise distribution of patients. 
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AGE 
(Years) 
MALE FEMALE 
TOTAL 
               (n=310) 
Number % Number % Number % 
21-30 18 5.86 10 3.22 28 9.03 
31-40 22 7.09 13 4.19 35 11.29 
41-50 53 17.09 31 10.00 84 22.09 
51-60 64 20.64 56 18.06 120 38.71 
61-70 31 10.00 12 3.87 43 13.87 
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3. Family history: 
Family history of the patients included in the present study is shown in Figure 2.It was 
observed that 121 (39.03%)  patients had a family history of  hypertension. Remaining of 
189(60.96%) having no family history of hypertension. 
 
 
 
Figure 3. Family history of patients 
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4. Treatment 
    In the present study drug prescription patterns were classified as single drug, dual drug 
and triple drug therapy. 
  The results revealed that, maximum number of patients 181(58.38%) underwent dual 
therapy followed by 95 (30.64%) underwent monotherapy and 34 (10.96%) were found to take 
triple drugs. It was also observed that in dual therapy and multiple therapy, most of the prescribed 
drugs are fixed dose combinations. The higher choice of fixed dose combination products offer a 
potential means of reducing pill burden and cost for the patient convenience and compliance. 
4.1 Single drug therapy 
The results revealed that, out of 310 patients who underwent antihypertensive therapy, 
95(30.64%) patients were found to be monotherapy. Table 3 & 3.1 shows the drug prescription 
pattern of mono therapy. In monotherapy, among 95 patients, 24 (25.26%) patients were found to 
be treated with CCBs, followed by 41 patients (43.15%) were treated with ARBs, 7 (7.36%)  
patients with ACE inhibitors, 8 (8.42%) of patients with beta blockers and 15 (15.79%)  patients 
with diuretics. The study showed the higher usage of ARBs as single drug in monotherapy 
followed by CCBs and Diuretics.  
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     Table 3. Single Drug prescribed for the patients.  
 
 
 
 
 
 
 
 
 
 
 
 
*-Angiotensin Converting Enzyme Inhibitor        
**-Angiotensin Receptor Blocker 
#-Calcium Channel Blocker 
##-Diruretics 
$-BetaBlockers 
 
                                                 
Further Sub-classify the mono drug therapy according to types of drug prescribed, the  
table3.1  expresst the higher usage of  Telmisartan 21(6.77%) followed by Amlodipine 15(4.84%) and 
the Least usage is Enlarpil,carvidelol,atenlol and diltiazem each 2 (0.65%). 
 
 
 
 
 
 Male Female Total (n=310) 
Drug type 
Number % Number % Number % 
ACEI
* 4 1.29 3 0.97 7 2.26 
ARB
** 21 6.77 20 6.45 41 13.23 
CCB
# 14 4.52 10 3.23 24 7.74 
DIR
## 8 2.58 7 2.26 15 4.84 
BB
$ 4 1.29 4 1.29 8 2.58 
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Table 3.1. Drug wise single Drug prescribed for the patients. 
Drug  
Male Female Total (n=310) 
Number % Number % Number % 
DIR 
Hcl
* 4 1.29 3 0.97 7 2.26 
Torsimide 4 1.29 4 1.29 8 2.58 
ACEI 
Enlarpril 1 0.32 1 0.32 2 0.65 
Ramipril 3 0.97 2 0.65 5 1.61 
ARB 
Losartan 5 1.61 4 1.29 9 2.90 
Olmisartan 5 1.61 3 0.97 8 2.58 
Telmisartan 11 3.55 10 3.23 21 6.77 
BB 
Atenlol 1 0.32 1 0.32 2 0.65 
Metaprolol 2 0.65 2 0.65 4 1.29 
Carvidelol 2 0.65   0.00 2 0.65 
CCB 
Amlodipine 9 2.90 6 1.94 15 4.84 
Diltiazem 5 1.61 4 1.29 9 2.90 
*-Hydrochlorthiazide 
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Figure 4. Pharmacological category of drugs prescribed in monotherapy. 
 
 
 
Figure 4.1 Prescription pattern of drugs in  Single drug therapy. 
 
 
 
 
0
2
4
6
8
10
12
14
ACEI
ARB
CCB
DIR
BB
%
 o
f 
p
at
ie
n
ts
Drugs combination
Male
Female
Total
0
5
10
15
20
25
%
 o
f 
p
at
ie
n
ts
Name of Drug
Male
Female
Total
Dept.of Pharmacy Practice, JKKN, Komarapalayam Page 49 
 
 
4.2 Dual drug therapy 
The graph 4.1  shows the prescription pattern of  dual drug therapy. Out of 310 
patients, for 181 (58,38%) patients ARB+DIR combinations were prescribed followed by  
ARB+CCB combinations in 53(29.28%) patients and ACE+DIR combinations in 21 
(11.60%) patients. In dual drug therapy the most used combinations are Telmisartan with 
Hydrochlorothiazide,  Telmisartan with Amlodipine and  Ramipril with Hydrochlorthiazide.      
 
  Table 4. Dual Drug prescribed for the patients. 
 
 
 
 
 
 
Drug 
Male Female Total (n=310) 
Number % Number % Number % 
BB+DIR 5 1.61 3 0.97 8 1.93 
ACEI+DIR 11 3.55 10 3.23 21 4.59 
ARB+DIR 40 12.90 32 10.32 72 16.23 
ARB+CCB 33 10.65 20 6.45 53 12.73 
ACEI+CCB 10 3.23 8 2.58 18 4.06 
BB+CCB 5 1.61 4 1.29 9 2.03 
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Table 4.1 Drug wise Prescription for Dual Drug Therapy for the patients 
 
Drug Type Male Female Total(n=310) 
BB+DIR Metaprolol+Hcl 5 3 8 
ACEI+DIR Ramipril+Hcl 11 10 21 
ARB+DIR Telmisartan+Hcl 21 19 40 
Olmisartan+Hcl 11 9 20 
Losaratan+Hcl 8 4 12 
ARB+CCB Telmisartan+Amlodipine 23 12 35 
Olmisartan+Amlodipine 10 8 18 
ACEI+CCB Ramipril+Amlodipine 10 8 18 
BB+CCB Metaprolol+Amlodipine 5 4 9 
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Figure 5. Pharmacological category of drugs prescribed in dual drug therapy. 
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Figure 5.1 Drug wise Double Drug prescribed for the patients 
 
 
4.3. Triple drug therapy 
Table.5. Triple Drug prescribed for the patients. 
 
 
Drugs 
Male Female Total      (n=310) 
Number % Number % Number % 
ARB+
CCB+
DIR 
Telmisartan+Amlodipine+Hcl 18 5.80 7 2.25 25 8.06 
Olmisartan+amlodipine+Hcl 6 1.95 3 0.96 6 1.95 
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Figure 6. Triple Drug prescribed for the patients. 
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6. DISCUSSION 
The aim of the work was to study the prescription pattern of  antihypertensive agents 
in hypertensive patients. A total of 310 patients were included in this study. All are different 
age group and having hypertension. Drug utilization studies are powerful exploratory tools to 
ascertain the role of drugs in society. They create a sound sociomedical and health economic 
basis for health care decision making.  It is one of the most effective methods to assess the 
prescribing pattern of physicians. 
AGE WISE DISRTRIBUTION 
120(38.71%) patients were fall in the age group of 51-60 years followed 84(22.09%) 
patients were in the age group of 41-50 years.  28(9.03%) patients  in the age group of 21-30 
years. 
FAMILY HISTORY 
In this study 30.96% of patients having family history of hypertension and rest of 
69.04% having no family history of hypertension. 
TREATMENT 
The study observed that the patients were received different type of antihypertensive 
agents depends upon their blood pressure level.  Most frequently used antihypertensive  are 
Angiotensin receptor blocker (13.23%), calcium channel blockers (7.74%), angiotensin 
converting enzyme inhibitors (2.26%), beta blockers (2.58%) and diuretics (4.54%). 
Totally single drug received patients are 30.64%, two drug received patients are 
58.38% and triple drug received patients are 10.96%. In  the study observed that there are 5 
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classes of two drug combination therapy were prescribed for some patients to control their 
blood pressure. And one type of triple drug combination were prescribed for some patients. 
Telmisartan is mostly prescribed for controlling and maintaining blood pressure for 
the patients who suffered from hypertension. The present study  also revealed that ARBs are 
mostly prescribed for the hypertensive patients in all age group in mono therapy and in over 
all utilization, followed by CCB especially telmisartan and amlodipine.  Diuretics are 
generally recommended as the first line therapy for the hypertension ( JNC V, JNC VI)
49
. 
Combination therapies were more when compared with mono therapy. 
 The high prescription rate of combination therapy may be due to high prevalence of 
patients with severe and moderate hypertension. Furthermore, the antihypertensive drug 
combination therapy should be able to minimize or counteract reflex compensatory 
mechanisms that often limit the fail in blood pressure.
 
In the present study two drug 
combinations (58.38%) mostly prescribed followed by mono therapy (30.64%). In the 
combination therapy Telmisartan with other anti hypertensives are high in usage to control 
the hypertension. Followed by olmisartan with hydrochlorthiazide and amlodipinie 
combinations. Utilization of calcium channel blocker in the present study is 7.74% with 
mono therapy, and overall utilization was (23.34%).  According to this study combination 
therapy is used more than monotheapy and showing the trend changing monotherapy to 
combination therapy.  
The choice of diuretics as the first line antihypertensive drug is consistent with JNC 
VII guidelines. Diuretics were one of the least prescribed drugs in our study which 
contradicts the standard guidelines for the treatment of hypertension. This could be due to its 
effect on the glucose homeostasis and lipid profile as most of our patients were in the elderly 
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age group. This study was conducted in small group of patients so more studies are 
recommended to have a better picture of the drug utilization pattern in the country in a large 
group of patients. This would improve the treatment strategies in the management of 
hypertension and also help in the effective use of the health care budget. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dept.of Pharmacy Practice, JKKN, Komarapalayam Page 57 
 
 
7. CONCLUSION 
Aim of the study was to evaluate the utilization of antihypertensive drugs in hypertensive 
patients. The study conclude that, 
1. ARBs are the most used antihypertensive agent especially Telmisartan.. 
2. ACEIs are the least prescribed antihypertensive agent. 
3. Double and triple combination therapies are more used when compared to 
monotherepy. 
4. In combination therapy ARB and Diuretics (16.23%) are placing the first place in 
prescription and followed by ARB and CCB (12.73%). The least combination was BB 
with Diuretics (1.93%). 
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